Recently, Shanghai Ligatech Bioscience Co., Ltd(利格泰), located in Qingpu District, Shanghai, announced the completion of a D round of financing of hundreds of Millions.
Founded in 2014, Ligatech is a sports medicine medical device developer, focusing on the provision of digital sports medicine products and solutions, dedicated to the development and manufacture of medical devices in the specialized field of sports medicine, as well as engaging in the research, development and production of biomedical materials and products.
The data on the official website of Ligatech shows that the company has more than 300 SCI publications relying on biplane imaging system technology, and the existing plant area is about 4,500 square meters, containing 1,500 square meters of class 10,000 purified production workshop and 200 square meters of class 10,000 aseptic inspection room. After obtaining the first domestic artificial ligament registration certificate in the first quarter, Ligatech has completed the overall layout of all consumables and equipment for sports medicine, consumables have been admitted to more than 2,000 hospitals, and small equipment has been installed in 200+ hospitals.
The global sports medicine market size was exhibited at USD 10.93 billion in 2022 and is expected to be worth around USD 21.86 billion by 2032, growing at a CAGR of 7.18% from 2023 to 2032. The demand for sports medicine has gained traction in recent years, owing to the rising incidences of sports injuries and growing participation in sports and fitness-related activities by people. In addition, a gradual shift from proactive care to preventive care with respect to sports injuries is further projected to drive the market.
The sports medicine market has great room for development, and a number of companies are competing for market share. Domestic companies include Kinetic(凯利泰), Rejoin(锐健医疗), and Yunyi(运怡医疗), while at the international level, there are large companies such as Arthrex, Depuy Synthes, and Stryker.
This round of financing was led by Xinda Kunpeng(信达鲲鹏), followed by Hangzhou Hanshi(杭州汉石), Jianxin Guomao(建信国贸) and Legend Capital(君联资本), an old shareholder of Ligatech, with Haoyue Capital(浩悦资本) acting as the exclusive financial advisor. Wang Junfeng(王俊峰), Co-Chief Investment Officer of Legend Capital, said that Ligatech already has a high reputation and a good clinical foundation in the domestic market, and has also started to enter the overseas markets. He believes that it is expected to become a sports medicine provider with global influence.